FDA Approves First Treatment for BCG-Unresponsive Papillary Bladder Cancer
The expanded approval for Anktiva plus BCG gives a new option to people whose high-grade tumors stopped responding to standard therapy.
The U.S. Food and Drug Administration on 14 October 2026 approved Anktiva (nogapendekin alfa inbakicept-pmln), used together with BCG, for adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has stopped responding to BCG. The agency describes it as the first approved treatment specifically for this group.
What changed
Anktiva was already approved for a related form of the disease called carcinoma in situ (CIS). The FDA said CIS and high-grade papillary tumors often occur together, are hard to tell apart under a microscope, and both carry a high risk of coming back or progressing once BCG stops working. The expansion therefore relies on the earlier CIS evidence plus those scientific similarities, rather than a new trial in papillary-only disease.
The evidence behind it
- In the 77-adult study supporting the original CIS approval, 62% had a complete response, meaning no high-grade cancer detected during follow-up.
- Among those responders, 58% kept the response for at least 12 months and 40% for at least 24 months.
- Treatment is given into the bladder through a catheter once weekly for six weeks, with further treatment depending on response, for up to 37 months.
"We listen to patients, clinicians, and researchers, and we act when the science supports a new approach." — R. Angelo de Claro, director of the FDA's Oncology Center of Excellence
Why it matters
People whose bladder cancer no longer responds to BCG often face the prospect of having the bladder removed. A new option for papillary-only disease gives patients and doctors another choice. The FDA is also finalizing guidance that would let CIS study evidence support approvals for this tumor type, which could speed future treatments.
Context
Side effects include painful or frequent urination, blood in the urine and urinary tract infections. The FDA warns that delaying bladder surgery can allow cancer to spread, which can be fatal, so decisions should be made with a specialist.
